AU · rank #17 · 2026-09-11
IMCD
AMSTERDAM · EUR · $6.74B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.717 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.09 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 8 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $117.36 | +19.1% |
| Momentum acceleration 3-month minus 12-month momentum. | +9.01% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.29 |
| Gross margin TTM | +25.0% |
| 52w high | $103.20 |
| Market cap (USD) | $6.74B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
IMCD NV is a global specialty chemicals distributor and formulator acting as a value-added intermediary between chemical suppliers and fragmented industrial and life science end-markets across multiple regions.
Rationale
With 90% revision agreement across 10 analysts, net upward EPS revisions accelerating over 30/60/90-day windows, and 19% analyst upside, the analyst_upside signal is reinforced by a genuine H1 2026 earnings beat and broad-based Q2 organic recovery that is prompting coordinated estimate upgrades rather than isolated outlier calls.
Material risks
- 1Gross margin compression (down ~70bps YoY to ~24.9%) from lower-margin acquisitions signals structural dilution of the distribution moat, the core concern for a name where pricing power versus pure specialty producers is already limited.
- 2Net leverage at 2.8x EBITDA constrains financial flexibility and amplifies downside if the cyclical volume recovery stalls or working capital needs rise, potentially reversing the free cash flow improvement that underpins current estimate momentum.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.